Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged
behind development of these drugs for treating cancers, due in part from concerns over the …

Systemic autoimmune disorders are complex heterogeneous chronic diseases involving
many different immune cells. A significant proportion of patients respond poorly to therapy. In …

Bruton's tyrosine kinase (BTK) is an intracellular signaling molecule first identified as the
molecule affected in X-linked agammaglobulinemia (XLA) patients, who almost completely …

Bruton's tyrosine kinase (BTK) mediates B cell signaling and is also present in innate
immune cells but not T cells. BTK propagates B cell receptor (BCR) responses to antigen …

Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of drugs that inhibit B cell
receptor activation, FC-γ receptor signaling, and osteoclast proliferation. Following on …

Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B‐cell biology and
function, highlighted by its position as a critical component of the B‐cell receptor signalling …

Bruton's tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family
that plays a key role in the intracellular signaling and proliferation, migration, and survival of …

Bruton's tyrosine kinase (BTK) is a member of the Tec tyrosine kinase family. 1 BTK is
expressed in most hematopoietic cells such as B cells, mast cells, and macrophages but not …

Highlights•This is an article originally prepared for Drug Discovery Today: Strategies.•The
article is now to be published in Drug Discovery Today.•The article forms part of a themed …

Bruton's tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor
signaling pathways. BTK is also involved in the regulation of Toll-like receptors and …